Better treatment for tuberculosis possible with biochemist's findings

Apr 16, 2012

Recent discoveries by a Virginia Tech biochemist could lead to a more effective drug design to combat the bacteria responsible for tuberculosis infection. Spread through the air from one person to another, tuberculosis is responsible for approximately two million deaths per year, worldwide, and the emergence of drug resistant forms, specifically MDR- and XDR-TB, is an escalating challenge.

Once a person is infected with tuberculosis, he or she typically faces four to six months of treatment, if it is even available, using a combination of as many as six drugs. Symptoms include chest pain, coughing up blood, weakness, fever, and chills.

Marcy Hernick, an assistant professor of biochemistry and affiliated faculty member with the Fralin Life Science Institute, has discovered that the amino acid tyrosine plays several key roles in one enzyme involved in the pathogenesis of , the bacteria that causes tuberculosis. Tyrosine aids in the regulation of the binding and release of small molecules, as well as the chemistry carried out by the enzyme.

"When studying pathogenesis, we wanted to map out the active site of the enzyme to understand which amino acid chains were necessary for catalysis to occur," Hernick said. "We found a tyrosine residue on the structure that we wouldn't have thought to be important. But, after further analysis, we think tyrosine moves to carry out different steps in the ."

This information will be useful in the field of drug inhibitor design, Hernick explained, because scientists will want to develop a drug that can interact with tyrosine in order to alter . Hernicks findings were published in the Journal of Biological Chemistry this month.

Explore further: Following a protein's travel inside cells is key to improving patient monitoring, drug development

Provided by Virginia Polytechnic Institute and State University

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New avenues for overcoming tuberculosis drug resistance

Apr 27, 2010

Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are al ...

Recommended for you

The anti-inflammatory factory

Apr 22, 2014

Russian scientists, in collaboration with their colleagues from Pittsburgh University, have discovered how lipid mediators are produced. The relevant paper was published in Nature Chemistry. Lipid mediators are molecules that p ...

Breakthrough points to new drugs from nature

Apr 16, 2014

Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds which could form the basis of novel therapeutic drugs.

User comments : 0

More news stories